In today’s briefing:
- CoreWeave Inc. (CRWV): IPO Valuation Is Fair for AI Industry Believers
- Deckers Outdoor: Ugg’s Profit Machine and Hoka’s Expansion—What Investors Need to Know!
- Fortive Corporation: How Its 2025 Spin-Off Could Reshape the Business!
- EPAM Systems: AI, Cloud & Expansion—Is This the Next IT Powerhouse?
- Alphabet’s $32 Billion Bet On Wiz: A Desperate Move or a Strategic Masterstroke?
- [ETP 2025/12] WTI Gains on Geopolitical Uncertainty, Henry Hub Falls on Rising Nat-Gas Stockpiles
- Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!
- Autodesk Under Seige: Activist Starboard’s Proxy Battle & What It Means for Shareholders!
- Enterprise Product Partners: How Is It Dealing With Export Market Volatility & Other Challenge?
- Bristol-Myers Squibb: EMERGENT-4 & Key Elements Of Its Therapeutic Pipeline That Could Shape Its Future!
CoreWeave Inc. (CRWV): IPO Valuation Is Fair for AI Industry Believers
- The valuation of the company in our opinion is “fair” and not “stretching the limit” for investors who believe in AI industry trends.
- A channel check of this offering revealed that the deal is considered well-oversubscribed with early 1-on-1 conversions and a strong shadow book.
- The company is a growth story through and through. They have grown from $16m in revenue in 2022 to $1.9bn in 2024 – the year-over-year growth in 2024 was 737%.
Deckers Outdoor: Ugg’s Profit Machine and Hoka’s Expansion—What Investors Need to Know!
- Deckers Brands delivered a robust performance in its third quarter of fiscal 2025, signaling both high levels of growth and notable profitability.
- The company’s revenue increased by 17% compared to the previous year, reaching $1.83 billion, with significant contributions from the UGG and HOKA brands.
- The gross margins improved to 60.3%, and diluted earnings per share rose by 19% to $3.
Fortive Corporation: How Its 2025 Spin-Off Could Reshape the Business!
- Fortive Corporation recently presented their fourth-quarter and full-year results, highlighting a combination of strengths and challenges that investors might consider when evaluating the company’s investment potential.
- Positive aspects of Fortive’s performance include a strong track record of financial accomplishments in 2024.
- The company reported better-than-expected core growth, adjusted earnings, and free cash flow, capping a robust year.
EPAM Systems: AI, Cloud & Expansion—Is This the Next IT Powerhouse?
- EPAM Systems Inc. reported its fourth quarter and full-year 2024 performance showing mixed results, noting both achievements and challenges.
- During the fourth quarter, the company experienced revenue growth of 7.9% on a reported basis, including the effects of recent acquisitions, NEORIS and First Derivative.
- On an organic constant currency basis, revenue grew a modest 1% year-over-year, marking a return to organic growth for the first time since early 2023.
Alphabet’s $32 Billion Bet On Wiz: A Desperate Move or a Strategic Masterstroke?
- Alphabet Inc., Google’s parent company, has officially announced its largest acquisition to date, agreeing to purchase cybersecurity startup Wiz for $32 billion in cash.
- The move comes after Wiz rejected a $23 billion offer from Alphabet last year, opting instead to explore an IPO.
- However, with the regulatory landscape shifting under U.S. President Donald Trump’s administration, Wiz’s leadership reconsidered the deal, ultimately securing an extra $9 billion from Google in less than a year.
[ETP 2025/12] WTI Gains on Geopolitical Uncertainty, Henry Hub Falls on Rising Nat-Gas Stockpiles
- For the week ending 14/Mar, U.S. crude inventories rose 1.7m barrels (vs. expectations of 0.8m build), gasoline stockpiles fell below expectations, and distillate inventories declined more than anticipated.
- US natural gas inventories rose by 9 Bcf for the week ending 14/Mar, more than analyst expectations of a 3 Bcf build. Inventories are 10% below the 5-year seasonal average.
- Barclays cut Exxon’s price target to USD 135 from USD 137 with an Overweight rating, while Citigroup lowered Occidental’s target to USD 51 from USD 56 with a Neutral rating.
Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!
- Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight into its strategic performance and outlook.
- The company, solely focused on structural heart solutions after divesting its Critical Care segment in the third quarter of 2024, recorded robust financial performance, consistent with its expectations and strategic focus.
- For the full year 2024, Edwards Lifesciences reported a 9% increase in sales, reaching $5.4 billion.
Autodesk Under Seige: Activist Starboard’s Proxy Battle & What It Means for Shareholders!
- Autodesk Inc. is at the center of a high-stakes battle as activist hedge fund Starboard Value LP moves forward with a proxy fight, citing financial underperformance and management credibility concerns.
- After months of behind-the-scenes pressure, Starboard has decided to nominate a minority slate of directors to Autodesk’s board, setting the stage for a potential leadership shake-up.
- The move comes after a series of turbulent events at Autodesk, including an accounting investigation that led to a CFO replacement, a shift in the company’s sales model, and a recent decision to cut 9% of its workforce.
Enterprise Product Partners: How Is It Dealing With Export Market Volatility & Other Challenge?
- Enterprise Products Partners LP reported its financial results for the fourth quarter of 2024, demonstrating both strengths and challenges within its extensive energy infrastructure network.
- In terms of financial performance, the company experienced a notable increase in adjusted cash flow from operations, which rose by 4% to $2.3 billion compared to the same quarter the previous year.
- Net income attributable to common unitholders also increased, registering a 3% rise to $1.6 billion or $0.74 per common unit.
Bristol-Myers Squibb: EMERGENT-4 & Key Elements Of Its Therapeutic Pipeline That Could Shape Its Future!
- Bristol-Myers Squibb’s (BMS) fourth quarter 2024 earnings call reveals a mixed outlook for the company.
- Positively, there were strong performances in certain areas of the company, reflecting a solid execution of its growth strategy.
- The growth portfolio delivered a double-digit increase, driven by key brands like Breyanzi, Camzyos, Reblozyl, and Opdualag.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
